FBT vs IBBQ

FBTBFirst Trust NYSE Arca Biotechnology Index Fund

IBBQAInvesco Nasdaq Biotechnology ETF

In short

FBT Biotech served in about 30 equal-sized bites. FBT has tracked the NYSE Arca Biotechnology Index since 2006, spreading each dollar evenly across a short roster instead of letting a few large caps run the show.

IBBQ The broad Nasdaq biotech benchmark, bought cheap. IBBQ tracks the whole listed biotech and pharma field, roughly 300 names, for 0.19% a year, well under half the typical fee in its category.

Stated mandate

FBT The fund seeks to track, before fees and expenses, the performance of the NYSE Arca Biotechnology Index.

IBBQ The Fund tracks the Nasdaq Biotechnology Index and normally invests at least 90% of its assets in index constituents. The index covers Nasdaq-listed companies classified as biotechnology or pharmaceutical companies.

Why people hold it

• FBT Equal weighting hands a small cap the same slot as a mega cap. About 30 names, each sized alike, so no single giant steers the fund.
• Live since 2006, through multiple biotech booms and busts, with a billion-dollar-plus asset base behind it.
• Moderately traded rather than a thin corner of the shelf, which matters in a sector where headlines arrive fast.
• Lands in the upper half of the biotech and genomics funds we grade.

• IBBQ At 0.19% a year, the lowest fee among its closest biotech rivals and less than half the category median.
• Holds roughly 300 Nasdaq-listed biotech and pharma companies, so one failed trial or one blockbuster is a slice of the fund, not the whole story.invesco.com
• Rules first: normally at least 90% of assets sit in Nasdaq Biotechnology Index constituents. No manager guessing which pipeline pays off.invesco.com
• Stands in the top quartile of the biotech and genomics funds we grade, keeping company with far larger rivals like XBI and IBB.

Worth knowing

• FBT At 0.55% a year it runs above the typical biotech fund's fee, and cheaper index routes exist (IBBQ at 0.19%, XBI at 0.35%).
• About 30 stocks, equally weighted, means one trial readout can swing the whole basket. Concentrated biotech moves hard in both directions.
• Not an income holding: drug developers plow cash into pipelines, and the fund has not been sending out distributions.

• IBBQ Thinly traded next to the category's giants, so bid-ask spreads can widen. Limit orders matter more here than in a heavily traded fund.
• One sector, and a jumpy one: biotech and pharma prices move on trial data and regulatory decisions, a rougher ride than a broad-market fund.invesco.com
• Launched in 2021, so a shorter live record and a smaller asset base than the category's long-standing funds.

Full FBT profile⁠

Full IBBQ profile⁠